The gene panel market is expected to grow at 20.02 % CAGR from 2023 to 2030. It is expected to reach above USD 13.2 billion by 2030 from USD 3.02 billion in 2023. List of the Top Key Players of the ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant's Shieldtm test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield test. The agreement ...

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer Guardant Health, Inc. (Nasdaq ...

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer PALO ALTO, Calif.--(BUSINESS ...